← Back to headlines
Truist Raises Vertex (VRTX) Price Target After Phase 3 Trial Results
Truist has increased its price target for Vertex Pharmaceuticals (VRTX) following the announcement of positive Phase 3 trial results.
24 Mar, 11:27 — 24 Mar, 11:27
Sources
Showing 1 of 1 sources
